These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26631582)

  • 1. Prolactin monitoring in the acute psychiatry setting.
    Perry BI; Goldring KJ; Menon SJ
    Psychiatry Res; 2016 Jan; 235():104-9. PubMed ID: 26631582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.
    Bushe C; Yeomans D; Floyd T; Smith SM
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):56-62. PubMed ID: 18477621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM; Wieck A
    Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprolactinemia associated with psychotropics--a review.
    Madhusoodanan S; Parida S; Jimenez C
    Hum Psychopharmacol; 2010; 25(4):281-97. PubMed ID: 20521318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
    Bushe C; Shaw M
    J Psychopharmacol; 2007 Sep; 21(7):768-73. PubMed ID: 17606473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
    Holzer L; Eap CB
    J Clin Psychopharmacol; 2006 Apr; 26(2):167-71. PubMed ID: 16633146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study.
    Park YM; Lee SH; Lee BH; Lee KY; Lee KS; Kang SG; Lee HY; Kim W
    Psychiatry Res; 2016 May; 239():184-9. PubMed ID: 27010188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications.
    Alosaimi FD; Fallata EO; Abalhassan M; Alhabbad A; Alzain N; Alhaddad B; Alassiry MZ
    Int J Psychiatry Clin Pract; 2018 Nov; 22(4):274-281. PubMed ID: 29334291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotics and hyperprolactinaemia: clinical recommendations.
    Peveler RC; Branford D; Citrome L; Fitzgerald P; Harvey PW; Holt RI; Howard L; Kohen D; Jones I; O'Keane V; Pariente CM; Pendlebury J; Smith SM; Yeomans D
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):98-103. PubMed ID: 18477626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.
    Cookson J; Hodgson R; Wildgust HJ
    J Psychopharmacol; 2012 May; 26(5 Suppl):42-51. PubMed ID: 22472310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.
    Holt RI
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):28-37. PubMed ID: 18477618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
    Roke Y; Buitelaar JK; Boot AM; Tenback D; van Harten PN
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):432-9. PubMed ID: 23234586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.
    Lawford BR; Barnes M; Connor JP; Heslop K; Nyst P; Young RM
    J Psychopharmacol; 2012 Feb; 26(2):324-9. PubMed ID: 21262859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
    Svestka J; Synek O; Tomanová J; Rodáková I; Cejpková A
    Neuro Endocrinol Lett; 2007 Dec; 28(6):881-8. PubMed ID: 18063941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychiatric Patients with Antipsychotic Drug-Induced Hyperprolactinemia and Menstruation Disorders.
    Takechi K; Yoshioka Y; Kawazoe H; Tanaka M; Takatori S; Kobayashi M; Matsuoka I; Yanagawa H; Zamami Y; Imanishi M; Ishizawa K; Tanaka A; Araki H
    Biol Pharm Bull; 2017; 40(10):1775-1778. PubMed ID: 28966250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the association between antipsychotic use and hyperprolactinaemia.
    Bushe C; Shaw M; Peveler RC
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):46-55. PubMed ID: 18477620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports.
    Haddad PM; Hellewell JS; Wieck A
    J Psychopharmacol; 2001 Dec; 15(4):293-5. PubMed ID: 11769824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprolactinaemia in early psychosis-not only due to antipsychotics.
    Aston J; Rechsteiner E; Bull N; Borgwardt S; Gschwandtner U; Riecher-Rössler A
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1342-4. PubMed ID: 20188136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin and smoking status in antipsychotic-treated patients.
    Mackin P; Waton A; Nulkar A; Watkinson HM
    J Psychopharmacol; 2011 May; 25(5):698-703. PubMed ID: 20699354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.